Prevention & lipidsSecondary analysis
Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study
- Secondary analysis of the Essence-TIMI 73b randomised trial
- placebo-controlled
- coronary CT angiography imaging study
Authors' conclusion
Despite substantial triglyceride and remnant cholesterol lowering, treatment with olezarsen for 12 months on top of standard-of-care lipid-lowering therapy in patients with largely moderate hypertriglyceridemia did not affect noncalcified coronary plaque volume.
Study context
- Population
- Adults with triglycerides ≥150 mg/dL, CVD or high CV risk, and noncalcified plaque on baseline coronary CT angiography
- Participants
- 468 adults
- Comparison
- Olezarsen vs placebo
- Olezarsenn = 349
- Placebon = 119reference
- Primary endpoint
- Percent change in noncalcified plaque volume
- Follow-up
- 12 months
Primary result
As reported in the abstract
Placebo-adjusted least-squares mean difference
2.98 %
95% CI −3.4 to 9.3
P = 0.36
Olezarsen vs Placebo
placebo-adjusted least-squares mean difference 2.98 % (95% CI −3.4 to 9.3); P = 0.36
Further findings
Triglycerides, remnant cholesterol, apoB, LDL-C (placebo-adjusted reduction) · 6 months
- Triglycerides reduced
- 63.9%
- Remnant cholesterol reduced
- 71.9%
- apoB reduced
- 16.0%
- No difference in LDL-C
Low-attenuation, calcified and total plaque volumes · 12 months
- No significant differences between olezarsen and placebo
Original publication
Effect of APOC3 Inhibition With Olezarsen on Coronary Atherosclerosis: Essence-TIMI 73b Imaging Study. Circulation. Published 30 March 2026. doi:10.1161/circulationaha.126.080012
Summarised from the published abstract; every number is checked against it